Fibrocell Science, Inc. Completes $9.1 Million Capital Raise
July 16 2012 - 5:45PM
Business Wire
Fibrocell Science, Inc. (OTCBB: FCSC) announced today that it
has completed a private placement originally commenced in May 2012
pursuant to which it raised an aggregate of $9.1 million through
the issuance of preferred stock and warrants.
John Carris Investments LLC and John Thomas Financial, Inc.
acted as co-placement agents for the transaction.
For complete details on the transaction, including the details
of the preferred stock and warrants, please see the Current Report
on Form 8-K filed with the Securities and Exchange Commission on
July 16, 2012.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy securities. None of the shares to
be issued to the investors nor the shares underlying the preferred
stock and warrants issued to the investors will be or have been
registered under the Securities Act of 1933, as amended, and may
not be offered or sold in the United States absent registration or
an applicable exemption from registration requirements.
About LAVIV™ (azficel-T)
LAVIV was approved by the FDA on June 21, 2011 for the
improvement of the appearance of moderate-to-severe nasolabial fold
wrinkles in adults and is the first and only personalized cell
therapy approved by the FDA for aesthetic use. LAVIV is now
available in major metropolitan areas throughout the U.S.,
exclusively through board-certified dermatologists and plastic
surgeons who have been trained by Fibrocell Science on the
treatment process. A list of trained and certified physicians is
available at www.mylaviv.com and will
be continually updated as new physicians are trained and begin
offering LAVIV in their practice.
Fibrocell Science is conducting research to identify other
potential uses of LAVIV and their proprietary fibroblast
technology. There is no timeline regarding when Fibrocell Science
will seek FDA regulatory approval for additional uses.
Important Safety Information About LAVIV™ (azficel-T)
LAVIV is made especially for you from your own skin cells. Using
someone else’s cells can cause a serious reaction. Prior to
injection, confirm with your physician that your information on the
LAVIV vial is correct. The most common side effects of LAVIV are at
the injection-site, including redness, bruising, swelling, pain,
bleeding, lumps, irritation, and itchiness. In clinical trials with
LAVIV, most injection-site adverse reactions resolved within one
week and most required no treatment. Your health care provider will
help you to decide whether you are a candidate for LAVIV and may
help you avoid some of the adverse reactions from LAVIV.
Before getting LAVIV, tell your healthcare provider if you have
any medical problems including allergic reactions to any drugs or
food, bleeding disorders or take blood-thinning medicines like
aspirin, ibuprofen, or Coumadin® (warfarin sodium), keloids or
excessive scarring, skin cancer or any malignancy, genetic
disorders affecting your skin, immune problems or take medicines
that affect your immune system, or any other illness or medical
problem. The full Prescribing Information for LAVIV includes
additional warnings about adverse reactions that occurred in less
than 1% of patients following LAVIV treatment in clinical trials.
Talk to your healthcare provider about these warnings. Please tell
your healthcare provider if you are allergic to the antibiotics
amphotericin or gentamicin, bovine materials (products made from
cattle), or dimethyl sulfoxide(DMSO).
Do not use LAVIV if you have a skin infection on your face
because LAVIV treatment can make the infection worse.
Please see the accompanying full prescribing information for
LAVIV contraindications, warnings, precautions and adverse events
or visit www.mylaviv.com.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (OTCBB:FCSC.OB) is an autologous
cellular therapeutic company focused on the development of
innovative products for aesthetic, medical and scientific
applications. Fibrocell Science is committed to advancing the
scientific, medical and commercial potential of autologous skin and
tissue, as well as its innovative cellular processing technology
and manufacturing excellence. For additional information, please
visit www.fibrocellscience.com.
Forward-Looking Statements
All statements in this press release that are not based on
historical fact are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995 and the
provisions of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. While management has based any forward-looking statements
contained herein on its current expectations, the information on
which such expectations were based may change. These
forward-looking statements rely on a number of assumptions
concerning future events and are subject to a number of risks,
uncertainties, and other factors, many of which are outside of the
Company's control, that could cause actual results to materially
differ from such statements. Such risks, uncertainties, and other
factors include, but are not necessarily limited to, those set
forth under Item 1A "Risk Factors" in the Company's Annual Report
on Form 10-K for the year ended December 31, 2011, as updated in
"Item 1A. Risk Factors" in the Company's Quarterly Reports on Form
10-Q filed since the annual report. The Company operates in a
highly competitive and rapidly changing environment, thus new or
unforeseen risks may arise. Accordingly, investors should not place
any reliance on forward-looking statements as a prediction of
actual results. The Company disclaims any intention to, and
undertakes no obligation to, update or revise any forward-looking
statements. Readers are also urged to carefully review and consider
the other various disclosures in the Company's public filings with
the SEC.